EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Current and emerging pharmacological treatment options for patients with dry eye disease

Feyza Cukurova, Giulia Coco iD, Filippo Lixi, Giuseppe Giannaccare iD

Expert Review of Clinical Pharmacology · 03.07.2025 · 18 (7) · 485-501

DOI: 10.1080/17512433.2025.2543380 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 07.08.2025. Verfasst von Feyza Cukurova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Department, Mardin Training and Research Hospital, Mardin, Turkey. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Drug Delivery Systems. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 160 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: To provide an up-to-date overview of current pharmacological treatments and promising emerging therapies for dry eye disease (DED), a multifactorial and increasingly prevalent ocular surface disorder. AREAS COVERED: A targeted literature search was conducted using PubMed, Scopus, ClinicalTrials.gov, and additional online sources to identify recent advances in the pharmacological management of DED. The review focuses on therapies approved across major regulatory bodies, as well as investigational agents in late-stage clinical development. Special attention is given to novel drug delivery platforms and innovative therapeutic mechanisms. EXPERT OPINION: Rapid innovation in both therapeutic targets and drug delivery technologies is transforming the treatment landscape for DED. Advanced formulations, such as nanomicelles, mucus-penetrating particles, and preservative-free emulsions, are improving ocular bioavailability, reducing adverse effects, and enhancing patient adherence. The future of DED pharmacotherapy lies in personalized, multimodal strategies that address the full spectrum of disease mechanisms, including inflammation, tear film instability, neurosensory dysfunction, and epithelial damage. The recent FDA approval of AR-15512, a TRPM8 agonist, exemplifies the trend toward mechanism-specific therapies designed to deliver both symptomatic relief and disease modification. As the therapeutic armamentarium expands globally, continued clinical trials and real-world studies will be essential to ensure durable efficacy and optimize patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dry Eye SyndromesDrug Delivery SystemsHumansAnimalsDrug DevelopmentMedication AdherenceBiological AvailabilityDrugs, Investigational

Stichwörter der Autor:innen

Dry eye diseasemucus-penetrating particlesnanomicellespharmacological treatmentspreservative-free emulsions

Substanzen

Drugs, Investigational

Autor:innen und Institutionen

  • Ophthalmology Department, Mardin Training and Research Hospital, Mardin, Turkey.
  • Ophthalmology Unit, Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Eye Clinic, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.

ORCID-Profile: Giulia Coco, Giuseppe Giannaccare

Zitieren

APA

Cukurova, F., Coco, G., Lixi, F., & Giannaccare, G. (2025). Current and emerging pharmacological treatment options for patients with dry eye disease. Expert Review of Clinical Pharmacology, 18(7), 485-501. https://doi.org/10.1080/17512433.2025.2543380

Vancouver

Cukurova F, Coco G, Lixi F, Giannaccare G. Current and emerging pharmacological treatment options for patients with dry eye disease. Expert Review of Clinical Pharmacology. 2025;18(7):485-501. doi:10.1080/17512433.2025.2543380

BibTeX
@article{Cukurova2025,
  author = {Cukurova, Feyza and Coco, Giulia and Lixi, Filippo and Giannaccare, Giuseppe},
  title = {Current and emerging pharmacological treatment options for patients with dry eye disease},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2025},
  volume = {18},
  number = {7},
  pages = {485--501},
  doi = {10.1080/17512433.2025.2543380}
}
Kostenlos starten →